Search Results for "insulin, regular"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for insulin, regular. Results 1 to 2 of 2 total matches.
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
at GIP and GLP-1 receptors, tirzepatide increases
insulin secretion, decreases glucagon secretion ...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
The Medical Letter ® Vol. 64 (1643) February 7, 2022
21
regularly in all patients. Increases in serum ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for
once-weekly subcutaneous (SC) treatment of growth
failure due to inadequate secretion of endogenous
growth hormone in children ≥1 year old who weigh
≥11.5 kg. It is the first once-weekly rhGH product to be
approved in the US; other available rhGH formulations
are administered more frequently.